- Sports News : Tonga coach welcomes Moana Pasifika, but with a warning for All Blacks [22/04/2021 - New Zealand]
- Business News : Despite severe COVID-19 impacts Vanuatu businesses remain optimistic [22/04/2021 - Vanuatu]
- News : Two new COVID-19 cases confirmed in Fiji [22/04/2021 - Fiji]
- News : Samoa could go back to the Polls [22/04/2021 - Samoa]
- News : Ocean benefits increasingly undermined by human activity, UN assessment reveals [22/04/2021 - United States]
- News : Biden administration considers protections for climate change refugees [22/04/2021 - United States]
- News : Chaos in PNG politics as prime minister adjourns parliament, avoiding no confidence vote [22/04/2021 - Papua New Guinea]
- News : Samoa caretaker PM Tuilaepa defends addition of woman MP [22/04/2021 - Samoa]
- News Feature : Biden Summit: Pacific Islands Climate Action Network calls on 40 leaders to pressure the U.S to increase its Green Climate Fund commitments [22/04/2021 - Vanuatu]
- Business News : New Zealand to open new Trade Commission in Fiji [22/04/2021 - Fiji]
- News : Samoa in "constitutional crisis" [22/04/2021 - Samoa]
- News : PNG’s COVID-19 cases surpasses 10,000 – death toll at 91 [22/04/2021 - Papua New Guinea]
- Sponsored : Oceania National Olympic Committees (ONOC)
The AstraZeneca COVID-19 vaccine could possibly cause rare blood clots in some people but further studies are required to confirm the link, experts with the World Health Organisation (WHO) said on Wednesday.
The opinion by the subcommittee of WHO’s Global Advisory Committee on Vaccine Safety (GACVS) follows a review of latest information from the European Medicines Agency (EMA), the United Kingdom’s regulatory body MHRA, and other countries.
The EMA concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of the AstraZeneca vaccine, while the MHRA said evidence of a link “is stronger but more work is still needed.” The UK has announced that it will offer an alternative shot to people under 30.
“Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors”, the WHO subcommittee said in an interim statement.
The AstraZeneca vaccine constitutes a large part of the portfolio of the COVAX global solidarity initiative, which has already shipped more than 36 million doses worldwide to more than 86 countries.
Though concerning, cases of blood clotting are very rare as low numbers have been reported among the nearly 200 million people worldwide who have received the vaccine, according to the statement.
“Rare adverse events following immunizations should be assessed against the risk of deaths from COVID-19 disease and the potential of the vaccines to prevent infections and reduce deaths due to diseases”, the subcommittee said.
The statement underlined the importance of vaccines against a disease which has killed some 2.6 million people worldwide, and that like all medicines, can have side effects.
“The administration of vaccines is based on a risk versus benefit analysis”, the subcommittee said.
Meanwhile, WHO is carefully monitoring the rollout of all COVID-19 vaccines, and will continue to work with countries to manage potential risks.
“In extensive vaccination campaigns, it is normal for countries to identify potential adverse events following immunisation”, the statement said. “This does not necessarily mean that the events are linked to vaccination itself, but they must be investigated to ensure that any safety concerns are addressed quickly.”.
SOURCE: UN NEWS CENTRE/PACNEWS
Pacific Islands News Association
Who & What is PINA?
International News Safety Institute (INSI)
Media Helping Media